1. Home
  2. SNGX

SNGX

Soligenix Inc.

Logo Soligenix Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Founded: N/A Country:
United States
United States
Employees: N/A City: PRINCETON
Market Cap: 5.7M IPO Year: 1987
Target Price: N/A AVG Volume (30 days): 2.7M
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.79 EPS Growth: N/A
52 Week Low/High: $0.37 - $4.20 Next Earning Date: 05-13-2024
Revenue: $839,359 Revenue Growth: -11.55%
Revenue Growth (this year): -2.78% Revenue Growth (next year): 25.00%

Share on Social Networks: